期刊文献+

奥沙利铂联合吡柔比星和氟尿嘧啶治疗晚期肝癌的临床疗效分析 被引量:15

Efficacy of oxaliplatin combined with pirarubicin and 5-fluorouracil for advanced hepatocellular carcinoma
暂未订购
导出
摘要 目的:探讨联合化疗方案治疗晚期原发性肝癌患者的有效性与安全性。方法:31例晚期原发性肝癌患者,采用奥沙利铂(L-OHP)、吡柔比星(THP)、氟尿嘧啶(5-FU)组成的联合方案进行化疗,观察和评价其疗效及毒副反应。结果:31例患者中,获得CR 0例,PR 9例,SD 14例,PD 8例,疾病控制率(DCR)74.2%;中位肿瘤进展时间(TTP)4.2月;中位生存期(OS)为10.2月;临床受益反应(CBR)率达77.4%;化疗后的血清AFP值较前明显下降。主要的毒副反应为骨髓抑制、消化道反应和感觉神经毒性。结论:奥沙利铂、吡柔比星、氟尿嘧啶组成的联合方案治疗晚期原发性肝癌的疗效安全可靠,不良反应可以接受。 Objective:To assess the efficiency and safety of systemic chemotherapy in the patients with histologically confirmed recurrent,metastatic,or unresectable hepatocellular carcinoma(HCC).Methods:Thirty one patients with advanced HCC were given systemic chemotherapy(THP 35mg/m2 iv d1;L-OHP 100-130mg/m2 ivgtt d1;CF 200mg/m2 ivgtt d1-2;5-FU 400mg/m2 iv d1-2,600mg/m2 civ 22h d1-2;or CF 400mg/m2 ivgtt d1;5-FU 400mg/m2 iv d1,2400mg/m2 civ 46h,repeated every 3-4 weeks).Tumor response,time to progression,survival,and toxicity were evaluated.Results:None of the patients had a complete response to treatment,9 patients obtained partial response,14 patients stable disease,8 patients disease progression;Median time to tumor progression(TTP) was 4.2 months,median overall survival(OS) 10.2 months.Compared to pre-treatment,there was a significant decrease of serum AFP level.The main toxic side effects included hematologic toxicity,alimentray tract reaction and neurotoxicity.Conclusion:The systemic chemotherapy regimen combined L-OHP,THP and 5-FU is a safe and effective therapy for patients with advanced HCC.All the adverse effects were well tolerable.
出处 《现代肿瘤医学》 CAS 2012年第10期2138-2140,共3页 Journal of Modern Oncology
关键词 原发性肝癌 奥沙利铂 吡柔比星 氟尿嘧啶 全身化疗 hepatocellular carcinoma oxaliplatin pirarubcin 5-fluorouracil systemic chemotherapy
  • 相关文献

参考文献6

二级参考文献30

  • 1高珲,赖大年,赵华洲,蔡斌,南菁,秦云霞.FOLFOX方案治疗晚期和转移性胃癌68例临床观察[J].现代肿瘤医学,2007,15(1):57-59. 被引量:9
  • 2姜明来,周玉霞,李万成.奥沙利铂和5-FU治疗晚期胃癌的疗效观察[J].医药论坛杂志,2007,28(2):25-27. 被引量:7
  • 3陈象逊,顾康生,梅蔚德,季楚舒.不同化疗方案治疗晚期胃癌的近期疗效观察[J].现代肿瘤医学,2007,15(7):984-986. 被引量:10
  • 4Hainsworth JD, Burris HA, Erland JB, et al. Phase Ⅰ study of docetaxel administered by weekly infusion in patients with advanced refractory cancer[J]. J Clin Oncol,1998,16(6) :2164-2168.
  • 5Llovet JM,Burroughs A,BruixJ.Hepatocellular carcinoma.Lancet 2003; 362:1907-1917
  • 6Llovet JM,Ricci S,Mazzaferro V,Hilgard P,Gane E,Blanc JF,de Oliveira AC,Santoro A,RaoulJL,Forner A,Schwartz M,Porta C,Zeuzem S,Bolondi L,Greten TF,Galle PR,Seitz JF,BorbathI,Haussinger D,Giannaris T,Shan M,Moscovici M,Voliotis D,Bruix J.Sorafenib in advancedhepatocellular carcinoma.N Engl J Med 2008; 359:378-390
  • 7Yeo W,Mok TS,Zee B,Leung TW,Lai PB,Lau WY,Koh J,Mo FK,Yu SC,Chan AT,Hui P,Ma B,LamKC,Ho WM,Wong HT,Tang A,Johnson PJ.A randomized phase III study of doxorubicin versuscisplatin/interferon alpha-2b/ doxorubicin/fluorouracil (PIAF) combination chemotherapyfor unresectable hepatocellular carcinoma.J Natl Cancer Inst 2005; 97:1532-1538
  • 8Gish RG,Porta C,Lazar L,Ruff P,Feld R,Croitoru A,Feun L,Jeziorski K,Leighton J,GalloJ,Kennealey GT.Phase III randomized controlled trial comparing the survival of patientswith unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin.J ClinOncol 2007; 25:3069-3075
  • 9Yeo W,Lam KC,Zee B,Chan PS,Mo FK,Ho WM,Wong WL,Leung TW,Chan AT,Ma B,Mok TS,JohnsonPJ.Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemicchemotherapy.Ann Oncol 2004; 15:1661-1666
  • 10Fardel O,Loyer P,Lecureur V,Glaise D,Guillouzo A.Constitutive expression of functionalP-glycoprotein in rat hepatoma cells.Eur J Biochem 1994; 219:521-528

共引文献84

同被引文献264

引证文献15

二级引证文献141

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部